Arkansas' Ezra Innovations is hoping its proprietary extended-release delivery tech can help it close a $6.5 million funding round.
John Lechleiter hasn't followed his peers into the mega-merger fray, believing that Eli Lilly ($LLY) can survive the loss of patents on key drugs with its internal R&D programs and via
Here's one bright spot today: Eli Lilly predicts a big year in 2008, with 14 percent growth in net profits and seven billion-dollar-plus products. Higher sales of drugs for depression (
While Eli Lilly's CEO was out lobbying for drug safety, the FDA was posting a letter on its website warning the drug maker to stop making "false and misleading" claims about its antidepressant
What do you do with a booming antidepressant? Broaden its scope, of course. Eli Lilly has filed for FDA approval to sell Cymbalta as a fibromyalgia remedy. It's already marketed for use against